Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers

Abstract

The GPR4 subfamily consists of four G protein-coupled receptors that share significant sequence homology. In addition to GPR4, this subfamily includes OGR1, TDAG8 and G2A. G2A has previously been shown to be a potent transforming oncogene for murine 3T3 cells. Here we show that GPR4 also malignantly transforms NIH3T3 cells and that TDAG8 malignantly transforms the normal mammary epithelial cell line NMuMG. Overexpression of GPR4 or TDAG8 in HEK293 cells led to transcriptional activation from SRE- and CRE-driven promoters, independent of exogenously added ligand. TDAG8 and GPR4 are also overexpressed in a range of human cancer tissues. Our results suggest that GPR4 and TDAG8 overexpression in human tumors plays a role in driving or maintaining tumor formation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Allen LF, Lefkowitz RJ, Caron MG and Cotecchia S . (1991). Proc. Natl. Acad. Sci. USA, 88, 11354–11358.

  • An S, Tsai C and Goetzl EJ . (1995). FEBS Lett., 375, 121–124.

  • Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA and Gerhengorn MC . (1998). Nature, 391, 86–89.

  • Choi JW, Lee SY and Choi Y . (1996). Cell Immunol., 168, 78–84.

  • Dumont JE, Jauniaux JC and Roger PP . (1989). Trends Biochem. Sci., 14, 67–71.

  • Fromm C, Coso OA, Montaner S, Xu N and Gutkind JS . (1997). Proc. Natl. Acad. Sci. USA, 94, 10098–10103.

  • Gupta SK, Gallego C and Johnson GL . (1992). Mol. Biol. Cell, 3, 123–128.

  • Gutkind JS . (1998). Oncogene, 17, 1331–1342.

  • Gutkind JS, Novotny EA, Brann MR and Robbins KC . (1991). Proc. Natl. Acad. Sci. USA, 88, 4703–4707.

  • Heiber M, Docherty JM, Shah G, Nguyen T, Cheng R, Heng HH, Marchese A, Tsui LC, Shi X, George SR and O'Dowd BF . (1995). DNA Cell Biol., 14, 25–35.

  • Im DS, Heise CE, Nguyen T, O'Dowd BF and Lynch KR . (2001). J. Cell Biol., 153, 429–434.

  • Julius D, Livelli TJ, Jessell TM and Axel R . (1989). Science, 244, 1057–1062.

  • Kyaw H, Zeng Z, Su K, Fan P, Shell BK, Carter KC and Li Y . (1998). DNA Cell Biol., 17, 493–500.

  • Ludwig MG, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U, Hofstetter H, Wolf RM and Seuwen K . (2003). Nature, 425, 93–98.

  • Mahadevan MS, Baird S, Bailly JE, Shutler GG, Sabourin LA, Tsilfidis C, Neville CE, Narang M and Korneluk RG . (1995). Genomics, 30, 84–88.

  • Marchese A, George SR, Kolakowski Jr LF, Lynch KR and O'Dowd BF . (1999). Trends Pharmacol. Sci., 20, 370–375.

  • Marinissen MJ and Gutkind JS . (2001). Trends Pharmacol. Sci., 22, 368–376.

  • Mayr BM, Canettieri G and Montminy MR . (2001). Proc. Natl. Acad. Sci. USA, 98, 10936–10941.

  • Nathanson NM . (2000). Proc. Natl. Acad. Sci. USA, 97, 6245–6247.

  • Radhika V and Dhanasekaran N . (2001). Oncogene, 20, 1607–1614.

  • Ridley AJ . (2004). Breast Cancer Res. Treat., 84, 13–19.

  • Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S and Pienta KJ . (2000). Clin. Cancer Res., 6, 1038–1045.

  • Russo D, Arturi F, Schlumberger M, Caillou B, Monier R, Filetti S and Suarez HG . (1995). Oncogene, 11, 1907–1911.

  • Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.

  • Stork PJ and Schmitt JM . (2002). Trends Cell Biol., 12, 258–266.

  • Subarsky P and Hill RP . (2003). Clin. Exp. Metastasis, 20, 237–250.

  • Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M and Kohno K . (2002). Anticancer Drugs, 13, 237–243.

  • Weng Z, Fluckiger AC, Nisitani S, Wahl MI, Le LQ, Hunter CA, Fernal AA, Le Beau MM and Witte ON . (1998). Proc. Natl. Acad. Sci. USA, 95, 12334–12339.

  • Whitehead I, Kirk H and Kay R . (1995). Mol. Cell. Biol., 15, 704–710.

  • Xu Y and Casey G . (1996). Genomics, 35, 397–402.

  • Zhu K, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JH, Witte ON and Xu Y . (2001). J. Biol. Chem., 276, 41325–41335.

  • Zohn IE, Klinger M, Karp X, Kirk H, Symons M, Chrzanowska-Wodnicka M, Der CJ and Kay RJ . (2000). Oncogene, 19, 3866–3877.

Download references

Acknowledgements

We would like to thank Ken Nguyen and Lei-Hoon See for excellent technical support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jianxin Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sin, W., Zhang, Y., Zhong, W. et al. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene 23, 6299–6303 (2004). https://doi.org/10.1038/sj.onc.1207838

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207838

Keywords

This article is cited by

Search

Quick links